First Patient Dosed in Phase 1 / 2a Trial Evaluating TUB-030 in Advanced Solid Tumors

A first patient was dosed in the clinical trial with TUB-030 (see: ADC Drug map), a 5T4-directed antibody-drug conjugate conjugated being developed by Tubulis built with ethynylphosphonamidate conjugation chemistry.